Alla studier
Aktiv men inte rekryterandeFAS3INTERVENTIONELL

Pivotal Study of N-acetyl-L-leucine for CACNA1A

This study is a research trial exploring a new potential treatment called N-acetyl-L-leucine (also known as IB1001) for individuals aged 4 and older who have a genetic condition related to CACNA1A. These conditions can include types of ataxia (problems with movement and balance) and certain severe migraines. Researchers want to understand if this new treatment is safe to use, how well people tolerate it, and if it can help improve symptoms compared to a placebo (a dummy pill with no active medicine). It's a 'Phase 3' study, meaning it's a key step in testing the treatment before it might be considered for wider use. The study is designed very carefully to get reliable results, involving participants receiving both the study medicine and the placebo at different times.

Överblick

Status
Aktiv men inte rekryterande
Fas
FAS3
Sponsor
IntraBio Inc
Inskrivningsmål
60
Starta
17 aug 2026
Beräknad slutförande
01 dec 2028

Vad handlar denna studie om?

This study is looking into a new medicine called N-acetyl-L-leucine, sometimes called IB1001, for people who have conditions linked to a gene called CACNA1A. These conditions can cause issues with movement and balance, like spinocerebellar ataxia type 6 and episodic ataxia type 2, or a type of severe headache known as familial hemiplegic migraine-1. Finding better ways to manage these conditions is really important for those affected and their families.

The main goal of this study is to see if N-acetyl-L-leucine is safe to use, if people can take it without too many difficulties (what we call 'tolerability'), and if it actually helps improve symptoms. To do this fairly, the new medicine is being compared to a 'placebo', which is a pill that looks the same but doesn't contain any active medicine. This helps researchers understand if any changes people feel are truly due to the new medicine or other reasons.

This is a 'Phase 3' study, which means it's a large and important step in testing the medicine. If it proves to be safe and effective in this phase, it could potentially become a treatment doctors can prescribe in the future. The study is being carried out in different centres and designed to be very thorough to make sure the results are as clear and reliable as possible.

Viktiga punkter

  • This study is testing a new medicine (IB1001) for CACNA1A-related conditions.
  • It's a 'Phase 3' trial, a key step in developing new treatments.
  • Participants will receive both the study medicine and a dummy pill at different times.
  • Children aged 4 and older, as well as adults, can participate.
  • Safety, tolerability, and effectiveness are the main things being studied.

Vem kan vara berättigad?

To join this study, you need to be at least 4 years old and have a confirmed diagnosis of a CACNA1A-related condition. This diagnosis must be based on genetic tests. Examples of these conditions include certain types of ataxia (problems with movement and balance) and some severe forms of migraine.

If you are a female and could potentially get pregnant, you can still take part, but you'll need to either be sexually inactive throughout the study or use a highly effective method of contraception. This is to ensure your safety and the accuracy of the study results. Your doctor can help explain which contraception methods are considered highly effective.

Females who are unable to get pregnant, either because they have had certain sterilisation procedures at least six months before starting the study, or who have gone through menopause at least a year ago, can also participate.

Kan denna studie passa dig?

Svara på dessa snabba frågor för att se om du kan vara berättigad. Detta är endast en vägledning — forskarteamet fattar det slutgiltiga beslutet.

  1. Are you aged 4 years or older?
  2. Do you have a genetically confirmed diagnosis of a CACNA1A-related condition?
  3. If you are female, are you using highly effective contraception or unable to get pregnant?
  4. Are you able to provide written consent for yourself or through a legal guardian?
Svara på varje fråga för att se ditt resultat.

Vad innebär deltagande?

If you decide to take part, the study will involve three main periods. First, there's a short 'baseline' period of about two weeks where doctors will get a starting picture of your health. After this, you'll be randomly assigned to either receive the study medicine (IB1001) or a placebo (a dummy pill) for about 12 weeks. Neither you nor your study doctor will know which one you are taking – this is called 'double-blinded'.

After these 12 weeks, you'll then 'switch over' to the other treatment (if you had the medicine, you'll get the placebo, and vice versa) for another 12 weeks. So, everyone in the study will get both the active medicine and the dummy pill at different times. During each of these periods, you'll have two assessment visits.

Once you complete the main part of the study, you might be offered the chance to join an 'Extension Phase'. This phase is designed to allow you to continue receiving the IB1001 medicine if you wish, providing continued access to the potential treatment.

Potentiella risker och fördelar

Taking part in any medical study has potential benefits and risks. A potential benefit of joining this study could be access to a new treatment that might help with your condition, which isn't yet widely available. However, there's no guarantee the treatment will work for you, and you might receive the placebo for a period. Potential risks involve side effects from the experimental medicine, which will be carefully monitored. You will be closely watched by medical staff throughout the study, and you have the right to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Platser (11)

  • Johns Hopkins universitet
    Verifierat postnummer
    Baltimore, USA
  • Massachusetts General Hospital
    Verifierat postnummer
    Boston, USA
  • The University of Texas Health (UT Health)
    Verifierat postnummer
    Houston, USA
  • Medical University of Innsbruck
    Verifierat postnummer
    Innsbruck, Österrike
  • University of Cologne
    Verifierat postnummer
    Köln, Tyskland
  • University of Athens
    Verifierat postnummer
    Aten, Grekland
  • University of Milan
    Verifierat postnummer
    Milano, Italien
  • Bambino Gesu' Children's Research Hospital
    Verifierat postnummer
    Rome, Italy
  • University Hospital Bern Inselspital
    Verifierat postnummer
    Bern, Schweiz
  • The Newcastle upon Tyne Hospitals NHS Foundation Trust
    Verifierat postnummer
    Newcastle upon Tyne, Storbritannien
  • University of Oxford - John Radcliffe Hospital
    Verifierat postnummer
    Oxford, Storbritannien

Vanliga frågor

What is CACNA1A?

CACNA1A is a gene, and problems with this gene can lead to conditions that affect movement, balance, and sometimes cause severe headaches.

Vad betyder 'placebo-kontrollerad'?

It means some people will get the active medicine, and some will get a dummy pill with no medicine inside. This helps researchers see if the real medicine is actually making a difference.

Vad är en 'Fas 3'-studie?

Phase 3 is an important stage where a new medicine is tested on a larger group of people to confirm its safety and how well it works before it can be considered for general use.

Kommer jag att veta om jag får den riktiga medicinen eller placebo?

No, neither you nor your study doctor will know which treatment you are receiving at any given time. This is done to keep the study fair and unbiased.

What is the 'Extension Phase'?

If you complete the main study, an Extension Phase might be offered, allowing you to continue receiving the active study medicine if you choose.

Hur du får reda på mer

Prata alltid med din läkare eller specialist innan du bestämmer dig för att delta i en studie.

Diskussion

Gemenskapsdiskussion

Drivs av vårt forum på community.patient.info. Var vänlig och respektfull — detta är inte medicinsk rådgivning.